To identify resistance mutations, the FGFRi-sensitive cell line NCI-H1581 (FGFR1 amplified lung cancer, but dependent only on FGFR2 signaling according to DepMap) was transduced and treated with either 20 nM pemigatinib or 10 nM futibatinib, two FGFRis in clinical use. This evidence concerns the gene FGFR2 and lung cancer.